At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 8, 2026 at 09:00 ET
Alpha Tau completed enrollment in its ReSTART pivotal trial (88 patients) for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, a key step toward FDA PMA approval. The company has Breakthrough Device Designation and submitted the first PMA module in January 2026. This milestone de-risks the regulatory pathway but approval and commercialization remain uncertain.
- Completed enrollment of 88 patients in ReSTART pivotal trial for recurrent cSCC.
- First U.S. pivotal study for Alpha Tau to complete enrollment.
- Alpha DaRT has FDA Breakthrough Device Designation for this indication.
- First module of modular PMA application submitted in January 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access